Refractory – Health

FDA Approves Xpovio (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

FDA Approves Xpovio (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Print this page NEWTON, Mass., July 03, 2019 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved oral Xpovio (selinexor), a nuclear export inhibitor, in combination… Read More »

VTA-DBS May Reduce Refractory Chronic Cluster Headache Frequency, Intensity – Clinical Pain Advisor

Deep brain stimulation in the ventral tegmental area (VTA-DBS) may effectively reduce the frequency and intensity of refractory chronic cluster headache and alleviate anxiety associated with headaches, according to a study published in Cephalalgia. A total of 18 consecutive patients with cluster headache who underwent VTA-DBS were included in the study. Patients were assessed prior… Read More »